Stock ScreenerStock IdeasStrong Buys According to Wall StreetStrong Buys According to Wall StreetCompanies with high upside and a consensus strong buy recommendation from Wall Street analysts
Stock ScreenerStock IdeasStrong Buys According to Wall Street
Consensus: Strong Buy
Analysts: >= 3
Upside/Downside: Large Upside
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BBOT | BRIDGEBIO ONCOLOGY THERAPEUTICS INC | $629.06M | $7.86 | $23.83 | 203.22% | Strong Buy | 6 | N/A | N/A | -38.92% | -35.68% | |||
| TYRA | TYRA BIOSCIENCES INC | $1.77B | $32.90 | $51.25 | 55.78% | Strong Buy | 8 | N/A | N/A | -50.97% | -46.74% | |||
| KGC | KINROSS GOLD CORP | $36.32B | $30.42 | $41.38 | 36.01% | Strong Buy | 4 | N/A | N/A | N/A | N/A | |||
| VKTX | VIKING THERAPEUTICS INC | $3.67B | $31.58 | $108.50 | 243.57% | Strong Buy | 4 | N/A | N/A | -41.43% | -34.19% | |||
| TRAX | FIRST TRACKS BIOTHERAPEUTICS INC | N/A | $17.82 | $41.00 | 130.08% | Strong Buy | 6 | N/A | N/A | -46.52% | -40.46% | |||
| BDTX | BLACK DIAMOND THERAPEUTICS INC | $155.83M | $2.72 | $11.00 | 304.41% | Strong Buy | 3 | -100.00% | N/A | -27.60% | -21.66% | |||
| GLUE | MONTE ROSA THERAPEUTICS INC | $1.59B | $19.81 | $32.00 | 61.53% | Strong Buy | 3 | -35.47% | N/A | -64.86% | -33.69% | |||
| BLLN | BILLIONTOONE INC | $4.27B | $92.90 | $122.43 | 31.79% | Strong Buy | 7 | N/A | N/A | N/A | N/A | |||
| LBRX | LB PHARMACEUTICALS INC | $917.02M | $31.98 | $40.33 | 26.12% | Strong Buy | 3 | N/A | N/A | -48.34% | -46.55% | |||
| DNLI | DENALI THERAPEUTICS INC | $3.13B | $19.71 | $36.33 | 84.34% | Strong Buy | 9 | N/A | N/A | -5.99% | -5.31% | |||
| NYXH | NYXOAH SA | $137.68M | $3.20 | $9.33 | 191.66% | Strong Buy | 3 | N/A | N/A | N/A | N/A | |||
| NEXN | NEXXEN INTERNATIONAL LTD | $217.54M | $7.73 | $11.07 | 43.22% | Strong Buy | 7 | N/A | N/A | N/A | N/A | |||
| CLYM | CLIMB BIO INC | $681.97M | $11.91 | $18.17 | 52.54% | Strong Buy | 12 | N/A | N/A | -115.90% | -112.64% | |||
| SRRK | SCHOLAR ROCK HOLDING CORP | $5.34B | $46.45 | $57.10 | 22.93% | Strong Buy | 10 | N/A | N/A | -5.89% | -3.57% | |||
| VIST | VISTA ENERGY SAB DE CV | $6.92B | $65.80 | $88.67 | 34.75% | Strong Buy | 3 | N/A | N/A | N/A | N/A | |||
| IDYA | IDEAYA BIOSCIENCES INC | $2.48B | $28.24 | $52.56 | 86.10% | Strong Buy | 9 | 1.02% | N/A | -4.36% | -3.97% | |||
| CLSK | CLEANSPARK INC | $3.58B | $13.98 | $18.00 | 28.76% | Strong Buy | 9 | 8.63% | N/A | -35.82% | -14.89% | |||
| EVER | EVERQUOTE INC | $728.69M | $20.60 | $26.75 | 29.85% | Strong Buy | 4 | 10.74% | -4.78% | N/A | N/A | |||
| SLDB | SOLID BIOSCIENCES INC | $695.63M | $7.07 | $18.17 | 156.96% | Strong Buy | 6 | N/A | N/A | 8.55% | 6.62% | |||
| PCVX | VAXCYTE INC | $7.43B | $51.48 | $105.00 | 103.96% | Strong Buy | 3 | N/A | N/A | -8.54% | -7.64% | |||
| CGEM | CULLINAN THERAPEUTICS INC | $890.94M | $14.72 | $33.40 | 126.90% | Strong Buy | 5 | N/A | N/A | -43.20% | -39.38% | |||
| SEPN | SEPTERNA INC | $1.08B | $23.98 | $40.33 | 68.19% | Strong Buy | 6 | 11.92% | N/A | -32.70% | -20.95% | |||
| CATX | PERSPECTIVE THERAPEUTICS INC | $410.16M | $3.60 | $12.63 | 250.69% | Strong Buy | 8 | 2.75% | N/A | -57.07% | -44.26% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.